IM Cannabis

IMCC · CANADIAN

$1.40−$0.10 (−6.67%)TodayMarket closed ·
Prev close $1.50

Latest news

  • Press releasePRNewswire

    IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet

  • Press releasePRNewswire

    IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares

  • Press releasePRNewswire

    IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • NewsAvi Kapoor

    Crude Oil Gains 1%; Cintas Earnings Top Views

  • NewsAkanksha Bakshi

    IM Cannabis Stock Falls after $1.31 Million Offering Follows Drone Deal

  • NewsAvi Kapoor

    Dow Falls 100 Points; General Mills Posts Upbeat Q1 Earnings

  • Press releasePRNewswire

    IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares

  • Press releasePRNewswire

    IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market

  • NewsAvi Kapoor

    Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August

  • NewsAvi Kapoor

    Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    US Stocks Mixed; Industrial Production Unchanged In August

  • Press releasePRNewswire

    IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing

  • Press releasePRNewswire

    IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance

  • NewsVandana Singh

    IM Cannabis Leverages Restructuring Deal to Reduce Financial Strain

  • News

    12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releasePRNewswire

    IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets

  • Press releasePRNewswire

    IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results

  • Press releasePRNewswire

    IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing

  • Press releasePRNewswire

    IM Cannabis Provides Corporate Update

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releasePRNewswire

    IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing

  • Press releasePRNewswire

    IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    IM Cannabis Announces Form F-3 Resale Registration Statement Filing

  • Press releasePRNewswire

    IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing

  • News

    IM Cannabis Q1 EPS $(0.28) Down From $0.06 YoY, Sales $6.343M Down From $8.708M YoY

  • Press releasePRNewswire

    IM Cannabis Corp. Announces First Quarter 2026 Financial Results

  • Press releasePRNewswire

    IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings

  • News

    'Trump Reclassifies State-Licensed Medical Marijuana As A Less-Dangerous Drug In A Historic Shift' - AP News

  • Press releasePRNewswire

    IMC Announces Receipt of Nasdaq Minimum Bid Price Notification

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • News

    IM Cannabis Lowers Warrant Exercise Price And Extends Expiry To 2030; Files Resale Registration For 4.98M Shares

  • Press releasePRNewswire

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.